A randomized controlled study to assess the effect of mosapride citrate on intestinal recovery following gastrectomy

Shiyeol Jun,Seyeol Oh,Ji Eun Jung,In Gyu Kwon,Sung Hoon Noh
DOI: https://doi.org/10.1038/s41598-024-57870-w
IF: 4.6
2024-03-27
Scientific Reports
Abstract:The enhanced recovery after surgery (ERAS) protocol, including prokinetic medications, is commonly used to prevent postoperative ileus. Prospective studies evaluating the effectiveness of mosapride citrate, a prokinetic 5-hydroxytryptamine 4 receptor agonist, in patients undergoing gastrectomy within the ERAS framework are lacking. This double-blind randomized trial included patients who were scheduled for laparoscopic or robotic gastrectomy for gastric cancer. Participants were randomly assigned to either a control (placebo) or experimental (mosapride citrate) group, with drugs administered on postoperative days 1–5. Bowel motility was evaluated based on bowel transit time measured using radiopaque markers, first-flatus time, and amount of food intake. No significant differences were observed in baseline characteristics between the two groups. On postoperative day 3, no significant difference was observed in the number of radiopaque markers visible in the colon between the groups. All factors associated with bowel recovery, including the time of first flatus, length of hospital stay, amount of food intake, and severity of abdominal discomfort, were similar between the two groups. Mosapride citrate does not benefit the recovery of intestinal motility after minimally invasive gastrectomy in patients with gastric cancer. Therefore, routine postoperative use of mosapride citrate is not recommended in such patients.
multidisciplinary sciences
What problem does this paper attempt to address?
This paper aims to evaluate the effect of mosapride on intestinal recovery after minimally invasive gastrectomy in gastric cancer patients. Specifically, the study aims to determine whether mosapride can provide additional benefits for patients undergoing minimally invasive surgery following the ERAS (Enhanced Recovery After Surgery) protocol. The study employed a double-blind randomized controlled trial design, randomly assigning patients to either the placebo group or the experimental group (mosapride group), and administering the respective drugs from postoperative day 1 to day 5. The recovery of intestinal motility was assessed by measuring the transit time of radiopaque markers, the time to first flatus, and food intake. However, the study results indicated that mosapride did not show significant advantages in these indicators. Therefore, the routine use of mosapride is not recommended for gastric cancer patients undergoing minimally invasive gastrectomy.